| 267 | 5 | 82 |
| 下载次数 | 被引频次 | 阅读次数 |
目的探究外用糖皮质激素(简称:激素)的重复治疗问题。方法选取2016年12月皮肤科门诊的全部处方84 110张,筛选出含激素处方34 398张。处方同时开具2种或以上含同等或相似强度激素的药品被判定为重复用药。结果激素重复治疗的处方达1 410张(4.1%)。超强效激素和强效激素重复使用占比合计43.3%,其中索咪新尿素乳膏和复方倍他米松乳膏联用占比最多,达26.4%。中效激素重复使用占比合计53.5%,其中复方曲安奈德乳膏和糠酸莫米松乳膏联用占比最多,达27.1%。结论激素重复治疗现象并不少见,医师对激素的相关认知需提高,临床药师应加强处方审核和评价,推动处方精简,提高激素的使用安全。
Abstract：AIM To study therapeutic duplications of topical corticosteroids(TCs) in the clinical application of dermatology. METHODS A total of 84 110 prescriptions of dermatology clinics were selected in December 2016, and 34 398 prescriptions containing TCs were screened out. Prescribing two or more drugs containing the same or similar potency of TCs at the same time was considered therapeutic duplication. RESULTS Of the 34 398 prescriptions containing TCs, 1 410(4.1%) were judged to be duplicative.The proportion of reuse of ultra high potency TCs and high potency TCs was 43.3%, in which the proportion of somexin urea cream combined with compound betamethasone cream was the highest, up to 26.4%.In total, 53.5 percent of the total amount of the moderate potency TCs was repeated, with the combination of compound triamcinolone acetonide cream and furfurate mormetasone cream taking the largest proportion, up to 27.1 percent. CONCLUSION Theraputic duplication of TCs is not uncommon clinically.Doctors need to improve their knowledge about classification by potency and adverse reactions of TCs.Clinical pharmacists should strengthen the audit and evaluation of prescriptions, promote prescription streamlining and improve the safety of TCs use.
[1] STEINMAN M A,LANDEFELD C S,ROSENTHAL G E,et al.Polypharmacyand prescribing quality in older people[J].J Am Geriatr Soc,2006,54(10):1516.
[2] O’MAHONY D,O’SULLIVAN D,BYRNE S,et al.STOPP/START criteria for potentially inappropriate prescribing in older people:version 2[J].Age Ageing,2015,44(2):213.
[3] PASINA L,ASTUTO S,CORTESI L,et al.Theraputic duplicates in a cohort of hospitalized elderlypatients:Results from the REPOSI study [J].Age Ageing,2016,33(9):647.
[4] LU H,XIAO T,LU B,et al.Facial corticosteroid addictive dermatitis in Guiyang City,China[J].Clin Exp Dermatol,2010,35(6):618.
[5] LIU Z H,DU X H.Quality of life in patients with facial steroid dermatitis before and after treatment[J].J Eur Acad Dermatol Venereol,2008,22(6):663.
[6] SINHA A,KAR S,YADAV N,et al.Prevalence of topical steroid misuse among rural masses[J].Indian J Dermatol,2016,61(1):119.
[7] VERMA S B.Topical corticosteroid misuse in India is harmful and out of control[J].BMJ,2015,351:h6079.
[8] MAHAR S,MAHAJAN K,AGARWAL S,et al.Topical corticosteroid misuse:the scenario in patients attending a tertiary care hospital in New Delhi[J].J Clin Diagn Res,2016,10(12):FC16.
[9] RATHOD S S,MOTGHARE V M,DESHMUKH V S,et al.Prescribing practices of topical corticosteroids in the outpatient dermatology department of a rural tertiary care teaching hospital[J].Indian J Dermatol,2013,58(5):342.
[10] 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组.规范外用糖皮质激素类药物专家共识[J].中华皮肤科杂志,2015,48(2):73.
[11] LAURA F.SANDOVAL D O,SCOTT A,et al.Dermatologists’ knowledge of and preferences regarding topical steroids[J].J Drugs Dermatol,2013,12(7):786.
[12] BEWLEY A,Dermatology Working Group.Expert consensus:time for a change in the way we adviseour patients to use topical corticosteroids[J].Br J Dermatol,2008,158(5):917.
[13] WOODWARD M C.Deprescribing:achieving better health outcomes forolder people through reducing medications[J].J Pharm Pract Res,2003,33(4):323.
[14] FARRELL B,POTTIE K,ROJAS-FERNANDEZ CH,et al.Methodology for developing deprescribing guidelines:using evidence and GRADE to guide recommendations for deprescribing[J].PLoS One,2016,11(8):e0161248.
[15] 闫晶超,沈剑文,陈念祖.我院2013年眼科门诊糖皮质激素类药物应用情况调查及处方点评难点[J].中国临床药学杂志,2015,24(2):113.
基本信息:
DOI：10.19577/j.1007-4406.2019.05.007
中图分类号:R95
引用信息:
[1]迟丹怡,王莹,李文艳,等.外用糖皮质激素处方的重复治疗评价[J].中国临床药学杂志,2019,28(05):351-354.DOI:10.19577/j.1007-4406.2019.05.007.
2019-09-25
2019-09-25